HIV MVA-CMDR vaccine

The **HIV MVA-CMDR vaccine** (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is an investigational recombinant viral vector vaccine candidate developed for the prevention and treatment of HIV-1 infection. It was created through a collaboration between the Laboratory of Viral Diseases (LVD) at the National Institute of Allergy and Infectious Diseases (NIAID) and the Walter Reed Army Institute of Research (WRAIR) / US Military HIV Research Program (MHRP). The vaccine utilizes a highly attenuated, non-replicating Modified Vaccinia Ankara (MVA) viral vector to express HIV-1 genes derived from circulating recombinant form CRF01_AE isolates from Chiang Mai, Thailand. Specifically, it expresses the *env* gene (gp150/gp160 from the CM235 isolate) and the *gag/pol* genes (from the CM240 isolate, with a deleted integrase and non-functional reverse transcriptase). The vaccine is designed to elicit robust cellular and humoral immune responses against HIV-1 and has been evaluated in Phase I and Phase II clinical trials, frequently as a heterologous boost following priming with HIV-1 DNA plasmid vaccines.

Other names

MVA-CMDR vaccineModified Vaccinia Ankara-Chiang Mai Double Recombinant vaccineHIV-MVA